Bruno Bockorny
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bruno Bockorny has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Constantin A. Dasanu
Department of Hematology-Oncology, St Francis Hospital and Medical Center, Hartford, CT
5 shared publications- Ion Codreanu
Department of Radiology and Imaging, State University of Medicine and Pharmacy “Nicolae Testemitanu”, Chisinau, Moldova
2 shared publications Anthony Posteraro
1 shared publication- Constantin A. Dasanu
Christus Health
1 shared publication - Joanna Grabska
University of Connecticut Medical Center, Department of Internal Medicine, 263 Farmington Avenue, Farmington, CT 06030, USA
1 shared publication Jonessa A. Atienza
Department of Internal Medicine, University of Connecticut Medical Center, Farmington, CT
1 shared publication
Latest Publications
- 1 April 2015
- Vol. 79 (4) , 197-200
Prevalence and Pattern of Autoimmune Conditions in Patients with Marginal Zone Lymphoma: A Single Institution Experience.
Increased risk of B-cell non-Hodgkin lymphoma (NHL) in patients with autoimmune diseases is a known fact. An association may exist between marginal zone lymphoma (MZL) and certain autoimmune conditions and vice-versa. Herein, we present the analysis of a series of consecutive patients (n = 24) diagnosed with MZL at our institution between 2008-2014. Our series, analyzed both retrospectively and prospectively, consisted of a blend of nodal, extranodal and splenic MZL. The median age was 71.8 years; M/F ratio was 2:1. The presence of autoimmune conditions was compared to their documented prevalence in the general population and tested for statistical significance using both chi-square test (χ2) and Fisher test for small number of observations (95% confidence). A P-value < 0.05 was considered significant. A total of 50% of MZL patients had documented autoimmune conditions. In addition, 3 of 24 patients presented with more than one autoimmune disease. Statistically significant differences in our MZL patients were recorded for immune thrombocytopenia [ITP] (P < 0.01), autoimmune hemolytic anemia [AIHA] (P < 0.01), Hashimoto thyroiditis (P = 0.037) and rheumatoid arthritis [RA] (P = 0.021). The difference did not reach statistical significance for systemic lupus erythematosus (SLE) and psoriasis. ITP and AIHA in our cohort were synchronous with MZL diagnosis in all patients, while all non-hematologic autoimmune conditions were metachronous and diagnosed prior to MZL. In the course of caring for patients with MZL, a number of associated autoimmune disorders are recognized. Knowing these entities is important not only for making a correct diagnosis, but also for being able to recognize certain clinical events occurring during the course of the disease. A catalogue of autoimmune disorders associated with this type of NHL is important as they can pose formidable clinical problems for the MZL patients and their physicians.
- 1 April 2015
- Vol. 79 (4) , 197-200
Prevalence and Pattern of Autoimmune Conditions in Patients with Marginal Zone Lymphoma: A Single Institution Experience.
Increased risk of B-cell non-Hodgkin lymphoma (NHL) in patients with autoimmune diseases is a known fact. An association may exist between marginal zone lymphoma (MZL) and certain autoimmune conditions and vice-versa. Herein, we present the analysis of a series of consecutive patients (n = 24) diagnosed with MZL at our institution between 2008-2014. Our series, analyzed both retrospectively and prospectively, consisted of a blend of nodal, extranodal and splenic MZL. The median age was 71.8 years; M/F ratio was 2:1. The presence of autoimmune conditions was compared to their documented prevalence in the general population and tested for statistical significance using both chi-square test (χ2) and Fisher test for small number of observations (95% confidence). A P-value < 0.05 was considered significant. A total of 50% of MZL patients had documented autoimmune conditions. In addition, 3 of 24 patients presented with more than one autoimmune disease. Statistically significant differences in our MZL patients were recorded for immune thrombocytopenia [ITP] (P < 0.01), autoimmune hemolytic anemia [AIHA] (P < 0.01), Hashimoto thyroiditis (P = 0.037) and rheumatoid arthritis [RA] (P = 0.021). The difference did not reach statistical significance for systemic lupus erythematosus (SLE) and psoriasis. ITP and AIHA in our cohort were synchronous with MZL diagnosis in all patients, while all non-hematologic autoimmune conditions were metachronous and diagnosed prior to MZL. In the course of caring for patients with MZL, a number of associated autoimmune disorders are recognized. Knowing these entities is important not only for making a correct diagnosis, but also for being able to recognize certain clinical events occurring during the course of the disease. A catalogue of autoimmune disorders associated with this type of NHL is important as they can pose formidable clinical problems for the MZL patients and their physicians.
- 1 December 2014
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (6) , 456-459
Autoimmune Manifestations in Patients With Waldenström Macroglobulinemia
- 1 December 2014
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 14 (6) , 456-459
Autoimmune Manifestations in Patients With Waldenström Macroglobulinemia
- 1 December 2012
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 12 (6) , 400-405
Autoimmune Manifestations in Large Granular Lymphocyte Leukemia
- 1 December 2012
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 12 (6) , 400-405
Autoimmune Manifestations in Large Granular Lymphocyte Leukemia
- 10 September 2012
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (2) , 435-437
Peripheral blood immunophenotypic analysis as a diagnostic tool for large granular lymphocyte leukemia
We read with great interest the recently published article of Watters et al. on large granular lymphocyte (LGL) leukemia [1]. The authors dissect LGL leukemia pathogenesis, discuss the diagnosis an...
- 10 September 2012
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 54 (2) , 435-437
Peripheral blood immunophenotypic analysis as a diagnostic tool for large granular lymphocyte leukemia
We read with great interest the recently published article of Watters et al. on large granular lymphocyte (LGL) leukemia [1]. The authors dissect LGL leukemia pathogenesis, discuss the diagnosis an...
- 1 August 2012
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 120 (2, Part 1) , 377-381
Bilateral Spontaneous Adrenal Hemorrhage During Pregnancy
- 1 August 2012
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 120 (2, Part 1) , 377-381
Bilateral Spontaneous Adrenal Hemorrhage During Pregnancy
- 16 April 2012
- Published by Wiley in British Journal of Haematology
- Vol. 158 (2) , 289
Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukaemia treated with cladribine ‐ Response to Jamroziak et al
- 16 April 2012
- Published by Wiley in British Journal of Haematology
- Vol. 158 (2) , 289
Poor prognosis of Hodgkin variant of Richter transformation in chronic lymphocytic leukaemia treated with cladribine ‐ Response to Jamroziak et al
- 24 October 2011
- Published by Wiley in British Journal of Haematology
- Vol. 156 (1) , 50-66
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
Summary: Richter transformation in chronic lymphocytic leukaemia (CLL) represents an entity of considerable genetic, molecular, immunological and clinical heterogeneity. A rare occurrence, Hodgkin variant of Richter syndrome, has not been comprehensively characterized or systematized to date. We conducted a retrospective analysis of the existing cases of Hodgkin lymphoma as Richter syndrome reported in the medical literature in the previous three and a half decades. Our search identified 86 such patients; this entity affects predominantly older men and the most common histological subtype is mixed cellularity. Interval between the diagnosis of CLL and subsequent development of Hodgkin lymphoma is circa 4·3 years. The overall survival of patients was approximately 1·7 years in our analysed cohort. However, our pooled data showed that patients in whom CLL had been treated with fludarabine had a shorter survival after transformation compared to the ones not treated with this agent. The role of immunosuppression and Epstein–Barr virus infection in the aetiopathogenesis of this entity remains to be clarified.
- 24 October 2011
- Published by Wiley in British Journal of Haematology
- Vol. 156 (1) , 50-66
Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature
Summary: Richter transformation in chronic lymphocytic leukaemia (CLL) represents an entity of considerable genetic, molecular, immunological and clinical heterogeneity. A rare occurrence, Hodgkin variant of Richter syndrome, has not been comprehensively characterized or systematized to date. We conducted a retrospective analysis of the existing cases of Hodgkin lymphoma as Richter syndrome reported in the medical literature in the previous three and a half decades. Our search identified 86 such patients; this entity affects predominantly older men and the most common histological subtype is mixed cellularity. Interval between the diagnosis of CLL and subsequent development of Hodgkin lymphoma is circa 4·3 years. The overall survival of patients was approximately 1·7 years in our analysed cohort. However, our pooled data showed that patients in whom CLL had been treated with fludarabine had a shorter survival after transformation compared to the ones not treated with this agent. The role of immunosuppression and Epstein–Barr virus infection in the aetiopathogenesis of this entity remains to be clarified.